Option chain shows key data for Oculis Holding's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Oculis Holding.

Oculis Holding (NASDAQ:OCS) Stock, Option Chain

Oculis Holding

Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

movers image

News

Intraday Update

Markets

Movers

Trading Ideas

MRUS

MVST

PCRX

RPRX

TALO

TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday

xr:d:DAFpQHWcfko:2,j:5894483215029085173,t:23072108

Pre-Market Outlook

ENPH

NOVA

RBBN

SEDG

SPWR

UROY

AutoNation, Baxter International And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

Google Parent Alphabet

Price Target

Analyst Ratings

FRPT

FSLR

GOOGL

TRGP

VRTX

Alphabet To Rally Over 28%? Here Are 10 Top Analyst Forecasts For Tuesday

Oculis Holding AG

Oaktree Specialty Lending Corporation - Closed End Fund

Oaktree Specialty Lending Corp

Press Releases

Oculis to Present at Upcoming September Investor Conferences

Health Care

Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award

Management

Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

Oculis' DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024

Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees

Earnings

Oculis Reports Q3 2024 Financial Results and Provides Company Updates

Oculis to Present at the Stifel 2024 Healthcare Conference

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy

Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares

Comments

Oculis Holding

Oculis Holding (OCS) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga